A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.

S KiruthikaRuchika BhatBhyravabhotla Jayaram Perumal Vivekanandan

Published in: The Journal of antimicrobial chemotherapy (2022)

The small molecule ZINC20451377 inhibits HBsAg and virion secretion in some of the clinically relevant drug-resistant HBV mutants. ZINC20451377 has a modest overall effect, and it was not effective against the MV mutants (lamivudine- and entecavir-resistant mutants).

Keyphrases

drug resistant
hepatitis b virus
small molecule
multidrug resistant
acinetobacter baumannii
protein protein
liver failure
wild type
oxide nanoparticles
cancer therapy
hiv infected patients
cystic fibrosis